The CD109 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HeLa cell line, engineered for targeted disruption of the CD109 gene to generate a loss-of-function model. This product provides a heterogeneous pool of cells carrying CD109 gene editing, enabling functional interrogation of CD109-dependent pathways without the constraints of single-cell clonal selection. The pooled format preserves population-level diversity and is suited for studying phenotypic variations that arise from dynamic signaling crosstalk in cancer biology.
HeLa cells are an extensively characterized immortalized cell line originating from a human cervical adenocarcinoma, constitutively expressing HPV18 oncoproteins E6 and E7. E6 targets p53 for ubiquitin-mediated degradation, while E7 inactivates the retinoblastoma protein (Rb), thereby disrupting cell cycle checkpoints. Combined with telomerase activation, these alterations confer a robust proliferative capacity, making HeLa cells a widely adopted model for investigating oncogenic signaling, tumor progression, and therapeutic responses in cervical cancer research.
CD109 encodes a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that functions as a context-dependent modulator of membrane-proximal signaling. Mechanistically, CD109 binds transforming growth factor-beta (TGF-beta) receptors TGFBR1 and TGFBR2, promoting their internalization and lysosomal degradation, which leads to diminished phosphorylation of the downstream transcription factors Smad2 and Smad3. Concomitantly, CD109 enhances epidermal growth factor receptor (EGFR) signaling, resulting in sustained activation of the PI3K/AKT/mTOR axis and extracellular signal-regulated kinase (ERK) phosphorylation, thereby shifting the cellular output from growth inhibition to proliferation and survival. Upstream regulators include TGF-beta itself, acting via Smad3, as well as interleukin-6 (IL-6), STAT3, and EGF. Documented molecular interactions involve Caveolin-1, while downstream effects include reduced phospho-Smad2/3, upregulation of c-Myc, and heightened ERK and AKT/mTOR pathway activity.
In the HeLa context, CD109 knockout provides a powerful tool to dissect the interplay between TGF-beta tumor-suppressive and tumor-promoting functions. The HPV-driven inactivation of p53 and Rb already attenuates canonical TGF-beta cytostatic responses; CD109 further perturbs this signaling by directing receptor trafficking and cross-activating EGFR-PI3K/AKT cascades. Consequently, loss of CD109 is expected to partially restore growth-inhibitory Smad signaling, alter migratory behavior, and modify sensitivity to TGF-beta ligands, enabling researchers to delineate CD109’s contribution to epithelial-mesenchymal transition (EMT) and drug resistance in cervical adenocarcinoma.
Typical research applications include monitoring TGF-beta dose-dependent growth inhibition via MTS/CCK-8 assays, assessing phospho-Smad2/3 and phospho-AKT levels by Western blotting, evaluating cell migration in transwell chambers, and quantifying expression of TGF-beta target genes such as p21 and c-Myc by RT-qPCR. The polyclonal population is also suitable for immunofluorescence localization of CD109, screening for small-molecule CD109 inhibitors, and investigating EGFR-TGF-beta crosstalk in drug sensitivity studies. For additional information, please contact Ascent Research.
